Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $2.37 million. The enterprise value is $236,313.
| Market Cap | 2.37M |
| Enterprise Value | 236,313 |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 3.70 million shares outstanding. The number of shares has increased by 536.72% in one year.
| Current Share Class | 3.69M |
| Shares Outstanding | 3.70M |
| Shares Change (YoY) | +536.72% |
| Shares Change (QoQ) | +119.79% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 0.91% |
| Float | 3.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.43 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.68 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -69.73 |
Financial Efficiency
Return on equity (ROE) is -672.22% and return on invested capital (ROIC) is -199.91%.
| Return on Equity (ROE) | -672.22% |
| Return on Assets (ROA) | -134.79% |
| Return on Invested Capital (ROIC) | -199.91% |
| Return on Capital Employed (ROCE) | -449.99% |
| Weighted Average Cost of Capital (WACC) | 11.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$808,793 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $17,000 in taxes.
| Income Tax | 17,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.14% in the last 52 weeks. The beta is 1.33, so CLDI's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -97.14% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 4.96 |
| Relative Strength Index (RSI) | 18.39 |
| Average Volume (20 Days) | 51,420 |
Short Selling Information
The latest short interest is 233,287, so 6.31% of the outstanding shares have been sold short.
| Short Interest | 233,287 |
| Short Previous Month | 231,117 |
| Short % of Shares Out | 6.31% |
| Short % of Float | 6.36% |
| Short Ratio (days to cover) | 1.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.85M |
| Pretax Income | -17.49M |
| Net Income | -23.46M |
| EBITDA | -16.14M |
| EBIT | -17.85M |
| Earnings Per Share (EPS) | -$33.30 |
Balance Sheet
The company has $4.07 million in cash and $1.94 million in debt, with a net cash position of $2.13 million or $0.58 per share.
| Cash & Cash Equivalents | 4.07M |
| Total Debt | 1.94M |
| Net Cash | 2.13M |
| Net Cash Per Share | $0.58 |
| Equity (Book Value) | 3.13M |
| Book Value Per Share | 1.50 |
| Working Capital | 2.19M |
Cash Flow
In the last 12 months, operating cash flow was -$17.75 million and capital expenditures -$94,000, giving a free cash flow of -$17.85 million.
| Operating Cash Flow | -17.75M |
| Capital Expenditures | -94,000 |
| Depreciation & Amortization | 1.71M |
| Net Borrowing | -522,000 |
| Free Cash Flow | -17.85M |
| FCF Per Share | -$4.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -536.72% |
| Shareholder Yield | -536.72% |
| Earnings Yield | -5,202.16% |
| FCF Yield | -763.87% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 31, 2026. It was a reverse split with a ratio of 1:16.
| Last Split Date | Jul 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |